The T cell-selective IL-2 mutant AIC284 mediates protection in a rat model of Multiple Sclerosis
| Autor: | Helga Rübsamen-Schaeff, Andreas Weishaupt, Daniela Paulsen, Niklas Beyersdorf, Sandra Werner, Nelli Wolf, Gabriele Köllner, Thomas Kerkau, Thomas Hünig |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Interleukin 2
Multiple Sclerosis medicine.medical_treatment T cell Immunology Antineoplastic Agents Autoimmunity Pulmonary Edema medicine.disease_cause T-Lymphocytes Regulatory Flow cytometry Antigens CD medicine Animals Immunology and Allergy Annexin A5 Cells Cultured Dose-Response Relationship Drug medicine.diagnostic_test business.industry Multiple sclerosis Experimental autoimmune encephalomyelitis Immunotherapy Flow Cytometry medicine.disease Coculture Techniques Recombinant Proteins Rats Killer Cells Natural Disease Models Animal medicine.anatomical_structure Neurology Rats Inbred Lew Interleukin-2 Female Neurology (clinical) business medicine.drug |
| Zdroj: | Journal of Neuroimmunology. 282:63-72 |
| ISSN: | 0165-5728 |
| DOI: | 10.1016/j.jneuroim.2015.03.020 |
| Popis: | Targeting regulatory T cells (Treg cells) with interleukin-2 (IL-2) constitutes a novel therapeutic approach for autoimmunity. As anti-cancer therapy with IL-2 has revealed substantial toxicities a mutated human IL-2 molecule, termed AIC284 (formerly BAY 50-4798), has been developed to reduce these side effects. To assess whether AIC284 is efficacious in autoimmunity, we studied its therapeutic potential in an animal model for Multiple Sclerosis. Treatment of Lewis rats with AIC284 increased Treg cell numbers and protected the rats from Experimental Autoimmune Encephalomyelitis (EAE). AIC284 might, thus, also efficiently prevent progression of autoimmune diseases in humans. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect